Singapore, Oct. 6 -- Terumo Blood and Cell Technologies (Terumo BCT), a medical technology company advancing blood- and cell-based therapies worldwide, has entered a research collaboration with TrAMPoline Pharma and Eduardo Davila, PhD, at the University of Colorado to develop an automated manufacturing approach for tumour-infiltrating lymphocyte (TIL) therapies targeting solid tumours.

The automated approach is intended to support manufacturing of TrAMPoline Pharma's lead therapeutic candidate, MightyTIL, as the company scales up for clinical trials.

Because TILs are derived from immune cells that have already infiltrated the tumour microenvironment, they are being explored as a promising approach for solid tumours, an area where tradi...